The albumin-bilirubin (ALBI) score predicts survival in patients with HCC and is recognized by the Barcelona Clinical Liver Cancer (BCLC) 2022 guidelines as a prognostic tool [13–15]. The gene discussed is ALB; the disease is hepatocellular carcinoma.